Ranbaxy fights back against the ban put by the Food and Drug Administration (FDA) in United States. FDA barred the supply of 30 drugs manufactured by Ranbaxy in its Indian manufacturing units located at Dewas and Paonta Sahib. Ranbaxy was against this ban of 30 drugs because it was manufacturing these drugs as per the standards mentioned by the FDA. Ranbaxy suffered the loss due to this strict action taken by the FDA. Ranbaxy mentioned that these drugs produced at the manufacturing unit in Dewas and Paonta Sahib are absolutely safe and are manufactured in the dust and germ free environment.
Ranbaxy was sure about the quality of the drugs manufactured at the Indian manufacturing units and submitted the documents that FDA had demanded to check the quality and safety standards of the products. The FDA in United States had requested to the court to hold the motion in abeyance for a reasonable period of time to allow Ranbaxy to produce the audit documents and to allow the government to confirm that all documents have been produced and to review Ranbaxy’s privilege log for claims of opinion work product. This does not mean that the US Food & Drug Administrator (USFDA) will stop its investigations against the Ranbaxy.
Ranbaxy has to suffer the losses, until FDA checks all the documents and gives company the clean chit. The spokesperson from the Ranbaxy said that we are fully cooperating with the US government and will provide, all documents required by the authorities. Ranbaxy CEO and MD Malvinder Singh said that it was ready to submit all audit documents sought by the US regulators. Ranbaxy India’s largest drug maker has submitted the audit reports and other documents of almost 500,000 pages last week are found to be complete.
FDA has asked the time till 6th October to review the documents and give its opinion on that. The spokesperson from the FDA said that the investigating team may visit the manufacturing units in India at Dewas and Paonta Sahib to check the safety standards as mentioned in the reports and then give a report to the US government about the approval or disapproval of the generic drugs manufactured by Ranbaxy in India. The US government has been unable to examine the 1,50,000 pages which were produced in last week by Ranbaxy. Additionally, images of some papers are of poor quality, and in some instances, illegible. Officials from Ranbaxy expect to resolve these issues soon. Ranbaxy has assured the government counsel that it intends to comply fully and will submit the new documents soon.
After checking about 1,50,000 documents the officials from the FDA has made a point that drugs manufactured by Ranbaxy are harmless. Still they are checking the further documents and will give the permission to sell drugs in United States after checking the safety standards followed by the manufacturing units at Dewas and Paonta Sahib in India. Thus, the spokesperson from Ranbaxy said that we will soon get back the permissions from FDA to sell these drugs in United States and will solve this problem as soon as possible.
Jeff Turner is an associated editor to the website Trustpharma.com. It is committed to provide visitors with complete information on generic drugs like generic viagra,kamagra,
caverta,Zenegra, Edegra, Silagra and online generic drugs by latest news, personal views, and articles on Mens Health related topics.
Please Rate this Article
Click the XML Icon Above to Receive Medicine Articles Via RSS!
